Biochemistry in the diagnosis and management of abnormal early pregnancy

Clinical Obstetrics and Gynecology

Volumn 50, Issue 1, 2007, Pages 55-66

  Chetty, Maya ^a,b   Elson, Janine ^a  

^a CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST   (United Kingdom)

^b SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

Author keywords

Biochemistry; Early pregnancy; Expectant management; hCG; Progesterone

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; HYDROXYPROGESTERONE; INHIBIN; INHIBIN A; INHIBIN PRO ALPHA C; METHOTREXATE; MISOPROSTOL; PROGESTERONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CHEMICAL PARAMETERS; ECTOPIC PREGNANCY; FIRST TRIMESTER PREGNANCY; HUMAN; MATHEMATICAL MODEL; PATIENT SELECTION; PREGNANCY COMPLICATION; PREGNANCY DISORDER; PROTEIN FUNCTION; SPONTANEOUS ABORTION;

ABORTION, SPONTANEOUS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INHIBINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PROGESTERONE;

EID: 33847106780     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318030571a     Document Type: Article

References (35)

1. Pittaway D, Reish R, Colston Wentz A. Doubling times of human chorionic gonadotrophin increase in early viable intrauterine pregnancies. Am J Obstet Gynecol. 1985;159:299-302.
2. Chetty M, Johnson AL, Chapman J, et al. Glycosylation of maternal serum hCG in early pregnancy. Unpublished data.
3. Light P, Russu V, Wildt L. On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial micro-environment: implications for differentiation and implantation. Sem Reprod Med. 2001;19:37-47.
4. Shepherd RW, Patton PE, Novy MJ, et al. Serial β-hCG measurements in the early detection of ectopic pregnancy. Obstet Gynecol. 1990;75:417-420.
5. Cacciatore B, Stenman U-H, Ylostalo P. Diagnosis of ectopic pregnancy by vaginal ultrasonography in combination with a discriminatory serum hCG level of 1000 IU/l (IRP). Br J Obstet Gynecol. 1990;7:904-908.
6. Stovall TG, Ling FW, Carson SA, et al. Nonsurgical diagnosis and treatment of tubal pregnancy. Fertil Steril. 1990;54:537-538.
7. Ankum WM, Van der Veen F, Hammerlunck JVTH, et al. Transvaginal sonography and human chorionic gonadotrophin measurements in suspected ectopic pregnancy: a detailed analysis of a diagnostic approach. Hum Reprod. 1993;8:1307-1311.
8. Barnhart KT, Simhan H, Kamelle SA. Diagnostic accuracy of ultrasound above and below the beta-hCG discriminatory zone. Obstet Gynecol. 1999;94:583-587.
9. Korhonen J, Stenman U-H, Ylostalo P. Serum human chorionic gonadotrophin dynamics during spontaneous resolution of ectopic pregnancy. Fertil Steril. 1994;61:632-636.
10. Elson J, Tailor A, Banerjee S, et al. Expectant management of tubal ectopic pregnancy: prediction of successful outcome using decision tree analysis. Ultrasound Obstet Gynecol. 2004;23:552-556.
11. Sowter MC, Farquhar CM, Petrie KJ, et al. A randomised trail comparing single dose systemic methotrexate and laparoscopic surgery for the treatment of unruptured tubal ectopic pregnancy. Br J Obstet Gynecol. 2001;108:192-203.
12. Condous G, Kirk E, Van Calster B, et al. Failing pregnancies of unknown location: a prospective evaluation of the human chorionic gonadotrophin ratio. BJOG. 2006;113:521-527.
13. Kirk E, Condous G, Haider Z, et al. The practical application of a mathematical model to predict the outcome of pregnancies of unknown location. Ultrasound Obstet Gynecol. 2006;27:311-315.
14. Stewart BK, Nazar-Stewart V, Toivola B. Biochemical discrimination of pathologic pregnancy from early, normal intrauterine gestation in symptomatic patients. Clin Chem. 1995;103:386-390.
15. Hahlin M, Thorburn J, Bryman I. The expectant management of early pregnancies of unknown site. Hum Reprod. 1995;10:1223-1227.
16. Banerjee S, Aslam N, Zosmer N, et al. The expectant management of women with early pregnancies of unknown location. Ultrasound Obstet Gynecol. 1999;16:231-236.
17. Banerjee S, Aslam N, Woelfer B, et al. Expectant management of early pregnancies of unknown location: a prospective evaluation of methods to predict spontaneous resolution of pregnancy. Br J Obstet Gynecol. 2001;108:158-163.
18. Hahlin M, Sjoblom P, Lindblom B. Combined use of progesterone and human chorionic gonadotrophon determinations for differential diagnosis of very early pregnancy. Fertil Steril. 1991;55:492-496.
19. Cunningham DS, Brodnik RM, Rayl DL, et al. Suboptimal progesterone production in pathologic pregnancies. J Reprod Med. 1993;301-303.
20. Aksoy S, Celikkanat H, Senoz S, et al. The prognostic value of serum estrodiol, progesterone, testosterone and free testosterone levels in detecting early abortions. Eur J Obstet Gynecol Reprod Biol. 1996;67:5-8.
21. Riss PA, Radivojevic K, Bieglemeyer C. Serum progesterone and human chorionic gonadotrophin in very early pregnancy: implications for clinical management. Eur J Obstet Gynecol Reprod Biol. 1989;32:71-77.
22. Elson J, Salim R, Tailor A, et al. Prediction of early pregnancy viability in the absence of an ultrasonically detectable embryo. Ultrasound Obstet Gynecol. 2003;21:57-61.
23. Ransom MX, Garcia AJ, Bohrer M, et al. Serum progesterone as a predictor of methotrexate success in the treatment of ectopic pregnancy. Obstet Gynecol. 1994;83:1033-1037.
24. Check JH, Vaze MM, Epstein R, et al. 17-hydroxyprogesterone level as a marker for corpus luteum function in aborters verus nonaborters. Int J Fertil. 1990;35:112-115.
25. Santoro N, Schneyer AL, Ibrahim J, et al. Gonadotophin and Inhibin concentrations in early pregnancy in women with or without corpoa lutea. Obstet Gynecol. 1992;79:579-585.
26. Lockwood GM, Ledger WL, Barlow DH, et al. Measurement of inhibin and activin in early human pregnancy: demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome. Biol Reprod. 1997;57:1490-1494.
27. Muttakrishna S, Bearfield C, Johns J, et al. Inhibin, activin, follistatin, activin receptors and β-glycan gene expression in the villous tissue of miscarriage patients. Mol Hum Reprod. 2004;10:793-798.
28. Glennon Phipps M, Hogan JW, Peipert JF, et al. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstet Gynecol. 2000;95:227-231.
29. Muttukrishna S, Jauniaux E, Greenwold N, et al. Circulating levels of inhibin A, activin A and follistatin in missed and recurrent miscarriages. Hum Reprod. 2002;17:3072-3078.
30. Lahiri S, Anobile CJ, Stewart P, et al. Changes in circulating concentrations of inhibins A and pro α-C during first trimester medical termination of pregnancy. Hum Reprod. 2003;18:744-748.
31. Illingworth PJ, Groome NP, Duncan WC, et al. Measurement of circulating inhibin forms during establishment of pregnancy. J Clin Endocrinol Metab. 1996;81:1471-1475.
32. 1 integrin and inhibits cytotrophoblast invasion into decidualized endometrial stromal cultures. GH IGF Res. 1998;8:21-31.
33. Elson J, Tailor A, Salim R, et al. Expectant management of miscarriage-prediction of outcome using ultrasound and novel biochemical markers. Hum Reprod. 2005;20:2330-2333.
34. Salim R, Miele J, Savvas M, et al. Session 17-endocrinology/basic: insulin-like growth factor binding protein-1 (IGFBP-1) assay in uterine flushings from women with a history of recurrent first trimester miscarriage and women with an incidental diagnosis of subseptate uterus. Hum Reprod. 2004;19(suppl):26.
35. Nielsen S, Hahlin M, Oden A. Using a logistic regression model to identify women with first-trimester spontaneous abortion suitable for expectant management. Br J Obstet Gynecol. 1996;103:1230-1235.